Apptly and Koning Announce Strategic Partnership to Expand Patient Access to Non-Compression 3D Breast Imaging

Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional News Services AI Disclosure Intelligence SEDAR+ About SEDAR+ SEDAR+ Resources EDGAR EDGAR Service Overview EDGAR Resources Webcasting and Conference Calling Newsroom Newsroom Newsroom Newswire Guidelines Sign Up for News Integrate Blog Contact Apptly and Koning Announce Strategic Partnership to Expand Patient Access to Non-Compression 3D Breast Imaging September 01, 2026 8:00 AM EDT | Source: Apptly Health Technologies Corp. Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the " Company " or " Apptly "), operator of the UberDoc direct-pay healthcare marketplace, today announced a strategic partnership with Koning Corporation (" Koning "), manufacturer of the FDA-approved Koning Vera Breast CT. Highlights: FDA-Approved Breast CT: The Koning Vera Breast CT is the only breast CT system with FDA premarket approval for diagnostic imaging of the breast. Market Access Model: Koning gains direct reach to patients already searching for care and ready to pay, while UberDoc adds imaging sites to its marketplace at transparent, upfront prices. Clinical Need: Mammography may miss an estimated 10-30% of breast cancers per the National Cancer Institute, rising to as much as 70% in women with extremely dense breast tissue per the American College of Radiology. Proven Technology at Scale: Koning Vera systems are installed in six countries and have been used to image more than 200,000 patients worldwide. The partnership is built around market access. Koning has spent more than a decade proving the clinical case for breast CT and placing systems in the field. What has been harder is closing the distance between a patient who needs the study, and a site that has the system. UberDoc solves for that distance directly: patients search, see the price, and book, without a referral and without a payer contract standing in the way. Under the agreement, Koning will display UberDoc physician and service listings within its platform and introduce its provider sites to UberDoc with the goal of onboarding them to the marketplace. Apptly, through UberDoc, will supply physician and service data along with trackable links that allow patients on Koning's platform to move directly into UberDoc to find and book an appointment. The companies will run joint marketing activity and will scope potential technology integrations for cash pay appointments over the course of the term. For patients, the effect is a shorter path between learning that advanced breast imaging exists and being able to schedule it. More specifically, a woman whose mammogram returns an inconclusive or difficult-to-read result by the clinician, particularly a woman with dense breast tissue, often faces a sequence of authorizations and unexplained costs before she reaches a next-step imaging study. With UberDoc, she can see which physicians offer the study, what it costs, and when appointments are available. The clinical need is well documented. According to the National Cancer Institute, mammography may not detect between ten and thirty percent of breast cancers, with misses frequently attributed to high breast density or fast-growing interval cancers. The American College of Radiology reports that for women with extremely dense breast tissue, up to seventy percent of cancers may go undetected by mammography alone. The Koning Vera Breast CT is indicated to provide three-dimensional images for diagnostic imaging of the breast and is intended to be read alongside standard two-view mammography. "Every physician has had the conversation where a patient is told her mammogram was inconclusive and that she needs further imaging, and then watches her disappear into a maze of authorizations. Some of those women never come back," said Dr. Paula M. Muto , Founder and Chief Executive Officer of the Company. "The constraint in specialty care is almost never demand. It is discovery, and it is price opacity. A patient cannot find the physician who has the equipment, and when she does find her, she cannot find out what it costs until after the fact. Koning built a device that gives radiologists a genuine three-dimensional look at the tissue without compressing it, and it is FDA approved for diagnostic use. Our job is to make sure a woman can find the physician who offers it, see what it costs before she commits, and get on the schedule this week rather than next quarter." "We have spent more than a decade bu